Funded research projects that name this disease in their title, terms or summary and have not ended yet: who is funded, where, how much and until when. Organisations only; the funder's page has the details.
NIH NCI · R43
Novel macrophage repolarization therapy for colorectal cancer
Panorama Research, Inc.· Sunnyvale, Egyesült Államok· 387 240 USD awarded in fiscal year 2026· until 2027. aug.
NIH NIAID · R01
Impact of bacterial phenotypic variation on phage resistance
Institute for Systems Biology· Seattle, Egyesült Államok· 874 085 USD awarded in fiscal year 2026· until 2031. aug.
NIH NINR · R01
Community Health Centers Achieving Metrics and Primed for Success
University of Pennsylvania· Philadelphia, Egyesült Államok· 762 815 USD awarded in fiscal year 2026· until 2031. jún.
NIH NCI · K99
Developing and Piloting a Multilevel Intervention to Address Nutritional Needs in the Outpatient Oncology Setting
Yale University· New Haven, Egyesült Államok· 168 290 USD awarded in fiscal year 2026· until 2028. aug.
NIH NCI · R01
The role of IL-9 in gastric metaplasia and carcinogenesis
Saint Louis University· Saint Louis, Egyesült Államok· 2 541 122 USD awarded in fiscal year 2026· until 2030. aug.
European Commission (Horizon Europe) · HORIZON-TMA-MSCA-PF-EF
Glycoanalytics-guided discovery of novel biomarkers and therapeutic glycoenzyme inhibitors for cancer (GLYCOANALYTICS)
I3s - Instituto de Investigacao e Inovacao Em Saude Da Universidade Do Porto· Porto, Portugália· EU contribution 207 183 EUR· until 2029. aug.
The disease is named only in the funder's project summary, not in the title.
European Commission (Horizon Europe) · HORIZON-TMA-MSCA-PF-EF
Unravelling Glycosylation Codes in Cancer at the Molecular Level: An Interdisciplinary Approach for the Dissection of the Recognition Features of CD44 by Galectins and Selectins (GLYCODECD44)
Asociacion Centro de Investigacion Cooperativa En Biociencias Cic Biogune· Derio Vizcaya, Spanyolország· EU contribution 194 075 EUR· until 2029. aug.
The disease is named only in the funder's project summary, not in the title.
European Commission (Horizon Europe) · HORIZON-TMA-MSCA-PF-EF
GUT-commensal Strain for Cancer Assessment and Notification (GUT-SCAN)
Vib Vzw· Zwijnaarde - Gent, Belgium· EU contribution 200 400 EUR· until 2029. márc.
The disease is named only in the funder's project summary, not in the title.
European Commission (Horizon Europe) · HORIZON-TMA-MSCA-PF-EF
Ion channelome of solid tumours: Novel immunotherapy targets for cancer-specific mRNA and drug delivery (ION-CANDEL)
Deutsches Krebsforschungszentrum Heidelberg· Heidelberg, Németország· EU contribution 217 965 EUR· until 2029. jan.
The disease is named only in the funder's project summary, not in the title.
European Commission (Horizon Europe) · HORIZON-TMA-MSCA-DN-JD
Target mining for the development of therapeutics against pathogen-induced cancers (TagTIC)
Paris-Lodron-Universitat Salzburg· Salzburg, Ausztria· EU contribution 4 281 580 EUR· until 2031. dec.· 9 countries
The disease is named only in the funder's project summary, not in the title.
10 of 1170 running projects, newest first. Listed amounts together: 662,6 M USD + 233,2 M EUR.
Sources: NIH RePORTER (U.S. National Institutes of Health, public domain) and CORDIS (European Commission, CC BY 4.0). Changes: filtered by disease, organisations matched to ROR.